Hydrocarbon Stapled HIV-1 GP41 Peptides for Proteolytic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development for viral infections, particularly HIV, faces challenges due to structural diversity and rapid mutation of viruses, leading to strain-specific antibody responses and limited effectiveness of existing vaccines in preventing viral infections.
Innovation Solution
Development of structurally constrained viral peptides, specifically targeting the membrane-proximal ectodomain region (MPER) of HIV, which are stabilized using hydrocarbon staples or amino acid modifications to enhance stability and immunogenicity, allowing for the generation of broadly neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional viral antigens are used for vaccine development, then the vaccine can be manufactured with standard methods, but the vaccine effectiveness is limited due to viral structural diversity and rapid mutation
Solution Approach 1:
The patent extracts and isolates the highly conserved MPER domain from the variable gp160 spike protein. By focusing on this specific conserved region that is shared across different HIV strains, the vaccine can elicit broadly neutralizing antibodies that are effective against multiple viral variants, thereby resolving the contradiction between vaccine effectiveness and viral strain coverage
Solution Approach 2:
The patent applies local quality by modifying specific properties of the MPER domain through hydrocarbon stapling and amino acid substitutions. These localized structural modifications enhance the stability and immunogenicity of the conserved region without altering its fundamental sequence, allowing the vaccine to maintain broad adaptability while improving reliability
2Stability of the object's composition
If native viral peptides are used as immunogens, then the peptide sequence is simple to design, but the peptide stability is poor due to proteolytic degradation
Solution Approach 1:
The patent changes the physical and chemical parameters of the peptide by introducing hydrocarbon staples and amino acid modifications. These parameter changes significantly enhance proteolytic resistance and structural stability while maintaining the immunogenicity of the MPER domain, resolving the contradiction between stability and structural complexity
Solution Approach 2:
The patent creates composite peptide structures by combining the native MPER amino acid sequence with non-natural hydrocarbon staple moieties. This composite approach integrates the immunogenic properties of the natural peptide with the enhanced stability of synthetic modifications, achieving both stability and controlled complexity
3Reliability
If the MPER domain is targeted for vaccine development, then broadly neutralizing antibodies can be generated, but the immunogenicity is reduced due to the region being shielded and difficult to access
Solution Approach 1:
The patent applies preliminary action by pre-organizing the MPER domain into a stable, pre-formed alpha-helical structure through hydrocarbon stapling. This pre-organization makes the conserved epitopes more accessible and recognizable to the immune system before antigen presentation, thereby enhancing the ability to generate broadly neutralizing antibodies despite the region's naturally shielded position
Solution Approach 2:
The patent utilizes the inherent curvature and three-dimensional folding of the MPER alpha-helix to present epitopes in a more accessible configuration. The hydrocarbon staples lock the peptide into a curved helical structure that mimics the native viral conformation while making key neutralizing epitopes more exposed to antibody binding, resolving the contradiction between generating BNAbs and immune system access
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The structurally constrained peptides demonstrate improved stability, proteolytic resistance, and enhanced immunogenicity, effectively inhibiting viral fusion and infection, and can overcome resistance to existing treatments, offering a promising approach for preventing and treating HIV infection.
Implementation Method 1
Hydrocarbon stapled alpha-helical gp41 heptad repeat domain peptides
Data Source
AI summary
The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating the viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.